ArticleMenopause (New York, N.Y.)2015
Compounded bioidentical hormone therapy: identifying use trends and knowledge gaps among US women.
Article in Menopause (New York, N.Y.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 63 citations in OpenAlex.
- Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.Menopause (New York, N.Y.) · 2019Trial
- Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.Menopause (New York, N.Y.) · 2019Trial
- Utilisation of hormone replacement therapy in Arab countries: a systematic review.Frontiers in global women's health · 2026Review
- Determination of estradiol and progesterone content in capsules and creams from compounding pharmacies.Menopause (New York, N.Y.) · 2019Article
- Women harmed by vaginal laser for treatment of GSM-the latest casualties of fear and confusion surrounding hormone therapy.Menopause (New York, N.Y.) · 2019Article
- Increased Incidence of Endometrial Cancer Following the Women's Health Initiative: An Assessment of Risk Factors.Journal of women's health (2002) · 2019Article
- Impact of 17β-estradiol on complex I kinetics and HThe Journal of biological chemistry · 2018Article
- Patterns of menopausal hormone therapy use and hyperkyphosis in older women.Menopause (New York, N.Y.) · 2018Article
- Why women choose compounded bioidentical hormone therapy: lessons from a qualitative study of menopausal decision-making.BMC women's health · 2017Article
- Prescribing of FDA-approved and compounded hormone therapy differs by specialty.Menopause (New York, N.Y.) · 2016Article
- Behaviours and attitudes influencing treatment decisions for menopausal symptoms in five European countries.Post reproductive health · 2016Article
- Compounded non-FDA-approved menopausal hormone therapy prescriptions have increased: results of a pharmacy survey.Menopause (New York, N.Y.) · 2016Article
- Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy.Menopause (New York, N.Y.) · 2016Review
- Article
- Patient considerations in the management of menopausal symptoms: role of conjugated estrogens with bazedoxifene.Therapeutics and clinical risk management · 2016Review
- Update on primary ovarian insufficiency.Current opinion in endocrinology, diabetes, and obesity · 2015Review
- Management of Menopausal Symptoms.Obstetrics and gynecology · 2015Review
Corrections and comments
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTwo surveys (Harris and Rose surveys) were conducted to quantify the use of compounded hormone therapy (CHT; or bioidentical hormone therapy) among perimenopausal and postmenopausal women in the United States, to assess women's knowledge of CHT versus Food and Drug Administration (FDA)-approved hormone therapy, and to gather information on menopausal experience.
methodsThe Harris survey was administered to 801 women aged 45 to 60 years who had experienced at least one menopausal symptom. The Rose survey was administered to 2,044 women aged 40 years or older who were ever users of hormone therapy. Women were queried about menopausal symptoms, hormone therapy use, and knowledge of CHT. Findings from the Rose survey were extrapolated using US Census Bureau data and prescription claims for FDA-approved hormone therapy to estimate the prevalence of CHT use.
resultsAccording to extrapolations using Rose data, up to 2.5 million US women aged 40 years or older may use CHT annually, accounting for 28% to 68% of hormone therapy prescriptions. Harris data showed that 86% of women surveyed were unaware that CHT products are not FDA-approved. The Rose survey asked a subset of 1,771 women whether their hormone therapy had been personalized based on hormone levels; 21% (378) answered "yes" whereas 27% (476) did not know. In both surveys, most hormone therapy users stated that their physician had recommended the treatment.
conclusionsWe estimate that 1 million to 2.5 million US women aged 40 years or older use CHT. The data suggest that many women are unaware that compounded hormones have not been evaluated or approved by the FDA. Providers have an educational opportunity to ensure that women considering hormone therapy understand the risks and benefits of inadequately regulated CHT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.